Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1

3(37.5%)

Early Phase 1

2(25.0%)

Phase 2

2(25.0%)

N/A

1(12.5%)

8Total

Phase 1(3)

Early Phase 1(2)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05396300Phase 1Recruiting

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

Role: lead

NCT07420010Early Phase 1Not Yet Recruiting

An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.

Role: lead

NCT06821048Phase 1Recruiting

Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

Role: lead

NCT05518253Phase 1Recruiting

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Role: lead

NCT05947201Phase 2Unknown

Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Role: lead

NCT05862168Phase 2Recruiting

Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial

Role: lead

NCT05372692Not ApplicableCompleted

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

Role: lead

NCT04652219Early Phase 1Completed

CART Therapy in GUCY2C-positive Digestive Tract Tumors

Role: lead

All 8 trials loaded